Prednisone is a synthetic, anti-inflammatory glucocorticoid that derives from cortisone. It is biologically inert and converted to prednisolone in the liver. Prednisone is an FDA-approved, delayed-release corticosteroid indicated as an anti-inflammatory or immunosuppressive agent to treat a broad range of diseases including immunosuppressive/endocrine, rheumatic, collagen, dermatologic, allergic states, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal (GI, acute exacerbations of multiple sclerosis, and as an anti-inflammatory and an antineoplastic agent. Prednisone is a corticosteroid (cortisone-like medicine or steroid). It works on the immune system to help relieve swelling, redness, itching, and allergic reactions. This medication is available only by prescription.
It is common for prednisone to be prescribed for other indications or in a different dosage than shown in the label information. These are called off-label prescribing or non-FDA-approved indications. Other countries may mention "approved" or "licensed" indications that do not apply in the United States.
Prednisone decreases inflammation via suppression of the migration of polymorphonuclear leukocytes and reversing increased capillary permeability. It also suppresses the immune system by reducing the activity and the volume of the immune system. The antineoplastic effects may correlate with the inhibition of glucose transport, phosphorylation, or induction of cell death in immature lymphocytes. It may have antiemetic effects by blocking the cerebral innervation of the emetic center via inhibition of prostaglandin.
Prednisone is a prodrug to prednisolone, which mediates its glucocorticoid effects. Prednisone is a synthetic glucocorticoid that has both anti-inflammatory and immunomodulating properties.
After cell surface receptor attachment and entry into the cell, prednisone enters the nucleus where it binds and activates specific nuclear receptors, which result in altered gene expression and inhibition of proinflammatory cytokine production. This agent decreases the number of circulating lymphocytes, inducing cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.
The effects of glucocorticoids are subject to mediation by mechanisms that alter DNA replication within the nucleus.
Prednisone may be administered orally with food or milk to decrease gastrointestinal upset. Maximal adrenal cortex activity occurs between 2:00 AM, and 8:00 AM am, and it is minimal between 4:00 pm and midnight. Exogenous corticosteroids suppress endogenous adrenocortical activity the least when administered during the time of maximal activity (the morning) for single-dose administration. Therefore, recommendations are that prednisone administration takes place in the morning before 9:00 AM, and when administering large doses, the patient should use antacids between meals to help prevent peptic ulcers. Multiple-dose therapy should have an even dose distribution in evenly spaced intervals throughout the day. Antacids also may be administered between meals to help prevent peptic ulcers.
The delayed-release tablets should be swallowed whole without breaking, dividing, crushing, or chewing. Administration of the oral solution should be with the provided calibrated dropper only. Other forms of steroids may be available if the oral formulation is not well-tolerated, for example, intramuscularly (IM), subcutaneously (SQ). Depending on the disease process, topical steroids may also be an option. It is best to take this medicine with food. Swallow the medication whole. Store the medicine in a tightly-closed container at room temperature, away from heat, moisture, and direct light. Do not freeze the oral liquid. Other routes of administration include liquid, solution, syrup, tablet, delayed-release tablets, nasal, rectal, injection, and intravenous.
Ask a patient if they are taking the following medications: aminoglutethimide, amphotericin B, carbamazepine, cholestyramine, cyclosporine, digoxin, isoniazid, ketoconazole, phenobarbital, phenytoin, or rifampin, a blood thinner (such as warfarin), NSAID pain or arthritis medicine (such as aspirin, diclofenac, ibuprofen, naproxen celecoxib), diuretic (water pill), diabetes medicine, a macrolide antibiotic (such as azithromycin, clarithromycin, erythromycin), estrogen (including birth control pills or hormone replacement therapy).
The primary adverse effects of prednisone include hyperglycemia, insomnia, increased appetite, hypertension, osteoporosis, edema, adrenal suppression, cataracts, and delayed wound healing.
Adverse effects are common in patients receiving glucocorticoids in high doses or over a long period. Potential adverse effects include skin fragility, weight gain, increased risk of infections, and fractures. Significant cardiovascular and metabolic effects are hypertension, hyperglycemia, and dyslipidemia.
Other adverse reactions include adrenal insufficiency, particularly when undergoing stressful procedures or during sepsis; this is typically diagnosable when the patient is hypotensive and not responsive to fluids, vasopressors, or cardiogenic medications. Once suspicion of adrenal insufficiency exists, treatment should be administered right away with a dose of 100 mg of hydrocortisone every eight hours.
Prednisone is contraindicated in patients with documented hypersensitivity to the drug or components of the formulation. Contraindications to the administration of prednisone include the presence of systemic fungal infections. Administering live or live-attenuated vaccines is also contraindicated with the administration of immunosuppressive prednisone doses.
It is essential to monitor for allergic reaction (itching or hives, swelling in your face or hands, swelling or tingling in your mouth or throat, chest tightness, trouble breathing), dark freckles, skin color changes, coldness, weakness, tiredness, nausea, vomiting, weight loss, rapid weight gain, depression, unusual thoughts, feelings, or behaviors, trouble sleeping, fever, chills, cough, sore throat, and body aches, muscle pain or weakness, swelling in your hands, ankles, or feet, severe stomach pain, red or black stools, skin changes or growths, trouble seeing, eye pain, or headache.
Clinicians must monitor patients with giant cell arteritis because increased cumulative glucocorticoid exposure was associated with an increased risk of glucocorticoid-related adverse effects.
Doctors can opt to track serum glucose, blood pressure, electrolytes, weight, bone mineral density, hemoglobin, occult blood loss, growth in pediatric patients, and infections. The HPA axis suppression should also undergo an assessment by morning cortisol test, adrenocorticotropic hormone stimulation test, and by measuring urinary free cortisol test.
When monitoring, it is essential to remember the elimination half-life of prednisone is 3 to 4 hours in adults and 1 to 2 hours in children.
More common symptoms to monitor are aggression, agitation, blurred vision, a decrease in the amount of urine, dizziness, irregular heartbeat or pulse, headache, irritability, mood changes, irregular breathing, numbness or tingling in the arms or legs, pounding in the ears, shortness of breath, swelling of the fingers, hands, feet, or lower legs, trouble thinking, speaking, or walking, difficulty with breathing at rest, or weight gain.
Like any anti-inflammatory agent, steroid toxicity is treated similarly to any non-steroidal anti-inflammatory drugs overdose or toxicity. Although the frequency of life-threatening complications from steroids and NSAID overdose is low, the overdose response ranges from no symptoms to death despite intensive-care treatment. Most symptoms are an excess of the pharmacological action of steroids and NSAIDs and include abdominal pain, nausea, vomiting, drowsiness, dizziness, headache, ear ringing, and nystagmus. A significant dose-response relationship occurs with the long-term use of systemic corticosteroids and the development of systemic corticosteroid-related complications for patients with severe asthma, resulting in an increased burden and costs on the health care system.
Managing drug adverse effects requires an interprofessional team of healthcare professionals that includes a nurse, laboratory technologists, pharmacist, and several physicians in different specialties. Without proper management, the adverse effects of prednisone overdose are high. Systemic corticosteroids have extensive use in the treatment of a variety of autoimmune and inflammatory disorders. Prolonged use, especially at high doses, can cause serious adverse effects. The most common systems involved include musculoskeletal, endocrine, cardiovascular, and central nervous system (CNS) and gastrointestinal (GI) tract. Prednisone's side effects can be minimized by monitoring the patient and putting preventative measures in place. Some of these preventative measures include using lower potency dosages and starting patients on the lowest effective dosage per guidelines. The patient needs to informed of the adverse effects so they may understand and be aware of making the proper lifestyle modifications to help reduce the risk of adverse effects. Patients should receive counsel to seek medical attention if they experience any of these known adverse effects. A steroid treatment card can be recommended to show to all healthcare professionals involved in their care and management. Adults versus children monitoring and care should be noted, particularly regarding growth curve complications, adrenal suppression, and osteoporosis.
To accomplish the above, interprofessional collaboration is crucial. Clinicians prescribe the drug, and need to inform the patients about the adverse event profile; this is often the task of the nursing staff. They can also assess patient compliance, and let the prescribing clinician know about any possible issues. Pharmacists can counsel the patient on proper administration, as well as reinforcing the adverse events. Pharmacists must also perform medication reconciliation, and report to the prescribing office regarding any potential interactions. Only through this type of interprofessional communication can prednisone therapy achieve its optimal results. [Level V]
|||Bunte K,Smith DJ,Chappell MJ,Hassan-Smith ZK,Tomlinson JW,Arlt W,Tiňo P, Learning pharmacokinetic models for in vivo glucocorticoid activation. Journal of theoretical biology. 2018 Oct 14 [PubMed PMID: 30048717]|
|||Martinez FJ,Lederer DJ, Focus on Idiopathic Pulmonary Fibrosis: Advancing Approaches to Diagnosis, Prognosis, and Treatment. Chest. 2018 Oct [PubMed PMID: 30290930]|
|||Puckett Y,Zhang K,Blasingame J,Lorenzana J,Parameswaran S,Brooks Md Facs SE,Baronia BC,Griswold J, Safest Time to Resume Oral Anticoagulation in Patients with Traumatic Brain Injury. Cureus. 2018 Jul 3 [PubMed PMID: 30186725]|
|||Bergmann TK,Barraclough KA,Lee KJ,Staatz CE, Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation. Clinical pharmacokinetics. 2012 Nov [PubMed PMID: 23018468]|
|||Ryu RJ,Easterling TR,Caritis SN,Venkataramanan R,Umans JG,Ahmed MS,Clark S,Kantrowitz-Gordon I,Hays K,Bennett B,Honaker MT,Thummel KE,Shen DD,Hebert MF, Prednisone Pharmacokinetics During Pregnancy and Lactation. Journal of clinical pharmacology. 2018 Sep [PubMed PMID: 29733485]|
|||Gale S,Wilson JC,Chia J,Trinh H,Tuckwell K,Collinson N,Dimonaco S,Jick S,Meier C,Mohan SV,Sarsour K, Risk Associated with Cumulative Oral Glucocorticoid Use in Patients with Giant Cell Arteritis in Real-World Databases from the USA and UK. Rheumatology and therapy. 2018 May 11 [PubMed PMID: 29752705]|
|||Dalal AA,Duh MS,Gozalo L,Robitaille MN,Albers F,Yancey S,Ortega H,Forshag M,Lin X,Lefebvre P, Dose-Response Relationship Between Long-Term Systemic Corticosteroid Use and Related Complications in Patients with Severe Asthma. Journal of managed care [PubMed PMID: 27348284]|
|||Liu D,Ahmet A,Ward L,Krishnamoorthy P,Mandelcorn ED,Leigh R,Brown JP,Cohen A,Kim H, A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology. 2013 Aug 15 [PubMed PMID: 23947590]|